Axert Related Published Studies
Well-designed clinical trials related to Axert (Almotriptan)
The impact of allodynia on the efficacy of almotriptan when given early in migraine: data from the "act when mild" study. [2011.12]
A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. [2011.06]
Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. [2011.01]
Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan. [2010.06]
Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. [2010.06]
Migraine treatment with rizatriptan and almotriptan: a crossover study. [2009.05]
Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. [2008.10]
Efficacy and Tolerability of Almotriptan in Adolescents: A Randomized, Double-Blind, Placebo-Controlled Trial. [2008.05.14]
Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan. [2008.04]
Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). [2007.02]
Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. [2006.05]
Effect of food intake on the bioavailability of almotriptan, an antimigraine compound, in healthy volunteers: an open, randomized, crossover, single-dose clinical trial. [2006.04]
A review of recent clinical experience with almotriptan. [2006]
Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg. [2005.10]
Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. [2005.07]
Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. [2005]
Pharmacokinetics and safety of oral almotriptan in healthy male volunteers. [2004.10]
Almotriptan improves response rates when treatment is within 1 hour of migraine onset. [2004.04]
Interaction between ketoconazole and almotriptan in healthy volunteers. [2003.04]
Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. [2002.12]
Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. [2002.07]
Use of rescue medication in trials of almotriptan versus placebo in the treatment of acute migraine. [2002.04]
Cardiovascular effect of almotriptan in treated hypertensive patients. [2002.03]
Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms. [2002.02]
Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials. [2002.01]
Almotriptan increases pain-free status in patients with acute migraine treated in placebo-controlled clinical trials. [2002.01]
Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis. [2002.01]
Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. [2001.11.27]
Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. [2001.11]
Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. [2001.06]
Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. [2001.05]
Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers. [2001.03]
Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. [2001.02]
Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. [2001.02]
Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. [2001.01]
Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. [2000.07]
Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. [2000.05]
Well-designed clinical trials possibly related to Axert (Almotriptan)
Gender and triptan efficacy: a pooled analysis of three double-blind, randomized,
crossover, multicenter, Italian studies comparing frovatriptan vs. other
triptans. [2014]
Efficacy of frovatriptan and other triptans in the treatment of acute migraine of
hypertensive and normotensive subjects: a review of randomized studies. [2013]
Frovatriptan vs. other triptans for the acute treatment of oral
contraceptive-induced menstrual migraine: pooled analysis of three double-blind,
randomized, crossover, multicenter studies. [2013]
Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention. [2009.03]
The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine. [2008.09]
Multiple attack study on the available triptans in Italy versus placebo. [2005.07]
Effects of symptomatic treatments on cutaneous hyperalgesia and laser evoked potentials during migraine attack. [2005.05]
Current perspectives on effective migraine treatments: are small clinical differences important for patients? [2003]
Clinical benefits of early triptan therapy for migraine. [2002.01]
Other research related to Axert (Almotriptan)
Improved patient satisfaction and pain evolution with almotriptan in migraine: a primary care study. [2011.03]
Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind,
placebo-controlled study. [2011]
Almotriptan: a review of 10 years' clinical experience. [2010.10]
Almotriptan for the acute treatment of adolescent migraine. [2010.10]
Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study. [2010.09]
Almotriptan 12.5 mg in menstrually related migraine: A randomized, double-blind, placebo-controlled study. [2010.07.26]
Long-term, open-label safety study of oral almotriptan 12.5 mg for the acute treatment of migraine in adolescents. [2010.05]
Almotriptan for the treatment of acute migraine: a review of early intervention trials. [2010.03]
Almotriptan: a review of 10 years' clinical experience. [2010]
Evolution of migraine-associated symptoms in menstrually related migraine
following symptomatic treatment with almotriptan. [2010]
Variation in almotriptan effectiveness according to different prophylactic treatments. [2009.10]
[Almotriptan vs. ergotamine plus caffeine for acute migraine treatment. A cost-efficacy analysis] [2009.04]
Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. [2008.10]
Almotriptan in triptan-naive patients: new evidence of benefits. [2008.09]
Seizure after use of almotriptan. [2008.09]
Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. [2008.07.15]
Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial. [2008.03]
Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. [2008.02]
Almotriptan, an antimigraine agent, and its malate salt. [2008.01]
Almotriptan: meeting today's needs in acute migraine treatment. [2007.12]
Use of almotriptan in triptan-experienced and triptan-naive patients. [2007.10]
Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. [2007.09]
Effect of Pain Intensity and Time to Administration on Responsiveness to Almotriptan: Results from AXERT((R)) 12.5 mg Time Versus Intensity Migraine Study (AIMS). [2007.04]
Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. [2007.03]
Patient preference in migraine therapy : A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. [2007.02]
Almotriptan and zolmitriptan in the acute treatment of migraine. [2007.01]
Ethanol does not significantly affect the bioavailability of almotriptan: an open, randomized, crossover, single-dose, phase I clinical trial in healthy volunteers. [2006.09]
Almotriptan in the acute treatment of migraine in patients 11-17 years old: an open-label pilot study of efficacy and safety. [2006.04]
Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. [2006.04]
Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example. [2006.02]
Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example. [2006.01.31]
Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. The migraine--satisfaction with treatment: reality with Almogran study. [2006]
Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine. [2005.11]
Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice. [2005.06]
Efficacy and tolerability of almotriptan in postmarketing surveillance studies. [2005]
Efficacy and tolerability of almotriptan in controlled clinical trials. [2005]
Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. [2005]
A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. [2004.05]
Oral almotriptan: practical uses in the acute treatment of migraine. [2004.05]
A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults. [2004.04]
Clinical profile and practice experience of almotriptan. [2004]
Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. [2003.11]
Early intervention with almotriptan improves sustained pain-free response in acute migraine. [2003.11]
Almotriptan versus rizatriptan in patients with migraine in Spain. [2003.07]
A review of the clinical efficacy and tolerability of almotriptan in acute migraine. [2003.07]
A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine. [2003.02]
[Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study] [2003.01]
Almotriptan: an effective and well-tolerated treatment for migraine pain. [2003]
Efficacy and safety of almotriptan malate for migraine. [2002.11.15]
Almotriptan, a new anti-migraine agent: a review. [2002.09]
How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. [2002.02]
Health outcomes evaluations: estimating the impact of almotriptan in managed care settings. [2002.02]
Almotriptan: a review of pharmacology, clinical efficacy, and tolerability. [2002.02]
Spotlight on almotriptan in migraine. [2002]
Fondaparinux sodium. [2002]
|
